News >

Acalabrutinib Shows Benefit in Ibrutinib-Treated Relapsed/Refractory CLL

Ellie Leick
Published: Monday, Aug 19, 2019

Kerry A. Rogers, MD

Kerry A. Rogers, MD
Acalabrutinib (Calquence) elicited high response rates, showed survival benefits, and had good tolerability in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who were intolerant to ibrutinib (Imbruvica) in a phase II trial, explained Kerry A. Rogers, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication